Parazole Dog/Cat 100 mg/ml Oral Suspension

Fenbendazole

Last verified

Veterinary medicinal product: oral suspension. Distribution category: AVM-GSL (Veterinary Medicines Regulations 2013, Schedule 3). Active substance: Fenbendazole.1

In short: questions and answers

Does Parazole Dog/Cat 100 mg/ml Oral Suspension need a prescription?
Over the counter. As stated in the registration decision.1
Which animals is Parazole Dog/Cat 100 mg/ml Oral Suspension for?
Cats, Dogs.1
What is the active substance in Parazole Dog/Cat 100 mg/ml Oral Suspension?
Fenbendazole. ATCvet code: QP52AC13.13
What is the withdrawal period of Parazole Dog/Cat 100 mg/ml Oral Suspension according to the leaflet?
No withdrawal period is set for this drug: it is not intended for food-producing animals.3
Dispensing
Over the counter1

AVM-GSL: Authorised Veterinary Medicine - General Sale List. No prescription is needed and it may be sold by any retailer.12

Supplied without a prescription. As stated in the registration decision.

Animal species
Cats1, Dogs1
Active substance
Fenbendazole
ATCvet code
QP52AC133
Manufacturer
Marketing authorisation holder: Foran Healthcare

Withdrawal period

No withdrawal period is set for this drug: it is not intended for food-producing animals.3

Summary of product characteristics

Composition

Each ml contains:

Active substance: 100 mg fenbendazole

Excipients:

Qualitative composition of excipients and other constituentsQuantitative composition if that information is essential for proper administration of the veterinary medicinal product
Methyl parahydroxybenzoate (E218)2.5 mg
Propylene glycol
Polysorbate 80
Xanthan gum
Simethicone emulsion
Purified water

A white to off-white suspension.

3

Pharmacological properties

4.1 ATCvet code: QP52AC13

4.2 Pharmacodynamics

Fenbendazole is an established anthelmintic which belongs to the benzimidazole group and is used primarily for its activity against nematodes.

Fenbendazole is an anthelmintic of the benzimidazole carbamate group which disrupts the energy metabolism of nematodes. The underlying mechanism of the anthelmintic action of fenbendazole is inhibition of the polymerisation of tubulin to microtubules. Fenbendazole is effective against adult and immature gastrointestinal nematodes.

Fenbendazole displays preference for parasitic as opposed to mammalian tubulin; this appears to be due to the fact that the formation of the parasitic tubulin-fenbendazole complex is more favourable kinetically under physiological conditions than the mammalian complex.

4.3 Pharmacokinetics

After oral administration fenbendazole is absorbed slowly and only partially. Following absorption from the digestive tract fenbendazole is metabolised in the liver to sulphoxide (oxfendazole) and further to sulphone and amine derivatives. Fenbendazole and its metabolites disperse slowly throughout the body, reaching high concentrations in the liver. Unchanged and metabolised fenbendazole is excreted primarily (>90%) with the faeces, and to a small extent also via the urine and milk.

3

Target species

Dogs and cats.

3

Indications

A broad spectrum anthelmintic for the treatment of domestic dogs and cats infected with immature and mature stages of nematodes of the gastrointestinal and respiratory tracts. Effective against immature and mature ascarids, hookworms and tapeworms. Also kills roundworm eggs.

3

Dosage

Oral use.

To ensure a correct dosage, body weight should be determined as accurately as possible.

Dose for routine worming of adult dogs and cats:

Shake well before use and administer a single dose at a dose rate of 100 mg/kg body weight which is equivalent to 1 ml per 1 kg body weight.

Dosage chart examples:

BodyweightVolume of Parazole
Adult Cat2 kg2 ml
4 kg4 ml
6 kg6 ml
Small Dog3 kg3 ml
5 kg5 ml
Medium Dog15 kg15 ml
25 kg25 ml
Large Dog35 kg35 ml
40 kg40 ml

Dose rate for weaned puppies and kittens under six months of age and lungworms in cats: Shake well before use and administer a single dose for 3 consecutive days at a rate of 50 mg/kg body weight which is equivalent to 1 ml per 2 kg body weight.

Puppies should be treated at 2 weeks of age, 5 weeks of age and again before leaving the breeder’s premises. Treatment may also be required at 8 weeks and 12 weeks of age.

Thereafter, frequency of treatment can be reduced unless the pups remain in kennels where reinfestation occurs more readily.

Dose rate for pregnant bitches:

Shake well before use and administer 1 ml per 4 kg body weight daily from day 40 of pregnancy continuously for approximately 25 days. This is equivalent to 25 mg fenbendazole /kg body weight daily.

Fenbendazole can be administered orally either directly into the mouth or alternatively it can be mixed in feed. Good mixing of the veterinary medicinal product in feed is advisable.

The suspension can be given using the 12 ml measuring syringe provided in the package. A syringe adaptor luer is also provided in the package.

Dosing procedure using the measuring syringe:

1. Estimate the body weight of the dog or cat accurately to ensure correct dosage.

2. To insert the syringe adapter (bung): Push down and unscrew bottle top. Position the syringe adapter (bung) and cap over the bottle opening. Push down firmly and screw cap into position. Syringe adapter (bung) should now be flush with the top of the bottle neck.

3. Shake bottle well before use. Push down and unscrew the bottle top. Insert the nozzle of the measuring syringe into the hole in the bung by gently pushing.

4. Turn the bottle/syringe upside down. Pull the syringe plunger out until the plunger corresponds to the required dose.

5. Turn the bottle right way up and with a twisting movement separate the measuring syringe from the bottle.

6. Push the plunger to empty the contents of the syringe directly into the mouth of the animal or onto the food. Good mixing of the veterinary medicinal product in food is advisable if it is to be given this way.

7. Depending on the dose required, repeat steps 3-6.

8. Replace bottle top after use.

3

Contraindications

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

3

Adverse reactions

Dogs and cats:

None known.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or the national competent authority via the national reporting system. See the package leaflet for respective contact details.

3

Warnings

Special precautions for safe use in the target species:

Ensure correct weight estimation and dose calculation.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

People with known hypersensitivity to fenbendazole or any of the excipients should avoid contact with the veterinary medicinal product.

Personal protective equipment consisting of impermeable gloves should be worn when handling the veterinary medicinal product. Wash hands after use.

Special precautions for the protection of the environment:

Not applicable.

3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance

Not applicable.

3

Use during pregnancy, lactation or lay

Pregnancy:

Can be used during pregnancy.

Lactation:

Can be used during lactation.

3

Interactions

None known.

It is advisable that the veterinary medicinal product is not mixed with other veterinary medicinal products.

3

Overdose

Benzimidazoles have a wide safety margin. It has been shown that at dosages up to 125 mg/kg, no toxic effect was observed. Little information is available for the cat – however fenbendazole is well tolerated at 150 mg/kg daily for 3 days.

3

Special warnings

Care should be taken to avoid the following practices because they increase the risk of development of resistance and could ultimately result in ineffective therapy:

• Too frequent and repeated use of anthelmintics from the same class, over an extended period of time.

• Underdosing, which may be due to underestimation of body weight or misadministration of the veterinary medicinal product.

3

Withdrawal period

Not applicable.

3

Incompatibilities

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

3

Immediate packaging

White, high density polyethylene bottle of 100 ml size with tamper evident child resistant closure.

Each 100 ml bottle is packed in a cardboard box and is supplied with a 12 ml polyethylene measuring syringe and a low density polyethylene syringe adaptor luer.

3

Storage

Do not freeze.

3

Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 3 years.

Shelf life after first opening the immediate packaging: 6 months.

3

Disposal of unused product

Medicines should not be disposed of via wastewater.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

3

Additional information

Vm 18576/4000

8 DATE OF FIRST AUTHORISATION

22 August 2018

9 DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS

May 2025

10 CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS

Veterinary medicinal product not subject to prescription.

Detailed information on this veterinary medicinal product is available in the Union Product Database (https://medicines.health.europa.eu/veterinary).

Approved 20 August 2025

3

Registration holder

Foran Healthcare

3

Regulations

Sources

  1. VMD Product Information Database: Parazole Dog/Cat 100 mg/ml Oral Suspension, 18576/4000 UK Veterinary Medicines Directorate (OGL v3.0), checked 2026-10-04 archived copy from 2026-10-04
  2. The Veterinary Medicines Regulations 2013, Schedule 3 (categories of veterinary medicinal products) UK Government, legislation.gov.uk, checked 2026-10-04 archived copy from 2026-10-04
  3. Summary of Product Characteristics: Parazole Dog/Cat 100 mg/ml Oral Suspension UK Veterinary Medicines Directorate, SPC of the marketing authorisation holder, checked 2026-10-04 archived copy from 2026-10-04

Other products with the same active substance

All products with this active substance (17)

The same active substance in other countries

These are different medicines with different authorisations. The dispensing status is the one on each product's own page, which gives its basis. The leaflet of the product in hand applies.

Spain

All products with this active substance (7)

Poland

All products with this active substance (4)

Ukraine

All products with this active substance (6)